Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

36.81
+1.694.81%
Post-market: 36.980.1745+0.47%18:59 EST
Volume:416.58K
Turnover:15.16M
Market Cap:748.77M
PE:-4.66
High:37.26
Open:35.18
Low:34.47
Close:35.12
52wk High:66.92
52wk Low:6.48
Shares:20.34M
Float Shares:17.59M
Volume Ratio:0.61
T/O Rate:2.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.8997
EPS(LYR):-8.6765
ROE:-180.24%
ROA:-27.97%
PB:8.80
PE(LYR):-4.24

Loading ...

Nektar Therapeutics Announces Inducement Stock Option Grant Under 2025 Plan

Reuters
·
Jan 31

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 31

Nektar Therapeutics Price Target Maintained With a $118.00/Share by BTIG

Dow Jones
·
Jan 30

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and LivaNova (LIVN)

TIPRANKS
·
Jan 26

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Reports Sale of Common Shares

Reuters
·
Jan 23

Septerna appoints Mark Wilson as chief legal officer

TIPRANKS
·
Jan 09

Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data

Benzinga
·
Dec 23, 2025

Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer

Reuters
·
Dec 17, 2025

Why Nektar Therapeutics (NKTR) Is Down 9.3% After Phase 2b REZOLVE-AA Data Readout And What's Next

Simply Wall St.
·
Dec 17, 2025

HC Wainwright Adjusts Nektar Therapeutics Price Target to $135 From $120, Maintains Buy Rating

MT Newswires Live
·
Dec 17, 2025

Nektar Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 17, 2025

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Benzinga_recent_news
·
Dec 17, 2025

BUZZ-Nektar falls after autoimmune disorder drug misses main goal in mid-stage study

Reuters
·
Dec 16, 2025

Nektar Therapeutics Shares Down 2.4% Premarket After Its Autoimmune Disorder Drug Misses Main Goal in Mid-Stage Study

THOMSON REUTERS
·
Dec 16, 2025

BRIEF-Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop

Reuters
·
Dec 16, 2025

Nektar Therapeutics - Both Rezpegaldesleukin Treatment Arms Met Statistical Significance Excluding Violations

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics - Rezolve-Aa Phase 2B Study Results Supports Advancement to Phase 3 Development in Alopecia Areata

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics - Rezpegaldesleukin Well Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics - Rezolve-Aa Phase 2B Study Achieved Target Product Profile With 28.2% Salt Score Reduction

THOMSON REUTERS
·
Dec 16, 2025

Nektar Study Establishes Proof-of-Concept in Patients with Severe Alopecia Areata

Dow Jones
·
Dec 16, 2025